GOP Committee Blocks Cannabis Rescheduling Despite Trump Support
Republican-led committee votes against marijuana rescheduling, creating tension with Trump administration's pro-cannabis stance and adding uncertainty to reform timeline.
A Republican-controlled congressional committee has voted to block marijuana rescheduling efforts, creating an unexpected rift with President Trump's evolving position on cannabis reform. The committee action represents a significant roadblock for the cannabis industry, which has been anticipating federal policy changes that could unlock institutional investment and banking services worth billions in market value.
The vote highlights growing fractures within the Republican Party on cannabis policy, as Trump has signaled openness to rescheduling while traditional GOP lawmakers maintain opposition. This internal conflict adds layers of uncertainty to reform timelines that cannabis companies have been factoring into their strategic planning and capital allocation decisions. Multi-state operators particularly face continued operational challenges without federal banking access and interstate commerce opportunities.
The committee's resistance comes as cannabis companies trade at significant discounts to traditional consumer goods peers, largely due to federal prohibition creating tax burdens and operational constraints. Without rescheduling, cannabis operators continue facing 280E tax provisions that prevent standard business deductions, directly impacting profit margins and cash flow generation across the sector.
Investors now confront a more complex political landscape where presidential support may not translate into legislative action. The disconnect between executive and congressional Republican positions creates additional volatility for cannabis equity valuations, which have historically moved sharply on federal policy developments. This political fragmentation suggests reform progress may face more resistance than previously anticipated.
The development forces cannabis companies to extend timelines for federal normalization while continuing to navigate state-by-state expansion strategies. With congressional Republicans pushing back against rescheduling despite Trump's position, the industry faces prolonged regulatory uncertainty that will likely keep institutional investors on the sidelines and maintain the sector's valuation discount to broader markets.